Mesar Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Mesar Plus is indicated for the management of hypertension, a condition affecting the cardiovascular system.

• Primary hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Secondary hypertension: provides effective control when hypertension is caused by another underlying condition.
• Hypertension with fluid retention: combines an ARB with a thiazide diuretic to reduce excess fluid and improve blood pressure control.

• Olmesartan medoxomil selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of water and electrolytes, which lowers plasma volume and further reduces blood pressure.

Mesar Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury
• Hyperkalemia
• Angioedema or severe allergic reaction
• Significant hypotension
• Liver function abnormalities

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure adequate control without excessive drop.
• Renal function assessment: check serum creatinine and eGFR regularly.
• Electrolyte surveillance: monitor potassium and sodium levels, especially with diuretics.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Concomitant medications: review for drugs that may potentiate hypotension or renal effects.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesar Plus can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Aliskiren (in patients with diabetes or renal impairment)
• Potassium‑sparing diuretics or supplements (risk of hyperkalemia)
• ACE inhibitors or other ARBs (combined effect may cause severe hypotension)
• Lithium (increased lithium levels and toxicity)
• NSAIDs (may reduce antihypertensive efficacy and impair renal function)

Moderate Interactions (Monitor Closely)

• Other antihypertensives (additive blood pressure lowering)
• Non‑selective beta‑blockers (enhanced hypotensive effect)
• Antidiabetic agents (possible need for dose adjustment due to blood pressure changes)
• Antimicrobials such as trimethoprim‑sulfamethoxazole (affects potassium balance)